The Biotech Growth Trust PLC (LSE:BIOG) reported NAV total return of 86.7% over the year to 31 August 2026, well ahead of the 52.5% gain in the NASDAQ Biotechnology Index, according to its latest monthly factsheet. In August itself, however, the trust lagged its benchmark, largely because it did not own Moderna.

What happened

The August factsheet showed a share price of 1,738.00p and NAV per share of 1,831.00p at the end of the month, a discount of 5.1%. The trust's website put net assets at £347.6m on the same date.

NAV rose 7.9% in August and the share price 8.5%, against 9.8% for the index. The factsheet said Moderna, which the trust did not hold, rose more than 150% during the month after positive Phase 3 data with Merck for a personalised mRNA cancer vaccine in melanoma, and was the main reason for the relative shortfall.

The trust also publishes portfolio updates, including one covering August 2026. There has been no fresh regulatory announcement from the company in the past two weeks.

Why it matters for investors

BIOG is a constituent of the FTSE All-Share index in the Closed End Investments sector and is managed by OrbiMed. It focuses on growth-stage biotechnology companies, which tend to be more volatile than large pharmaceutical groups.

The board's discount policy is relevant. It aims to keep the discount to NAV at no more than 6% through share buybacks, with repurchased shares cancelled. The August discount of 5.1% was inside that target.

The longer-term figures also show the trust ahead of its index. Over three years the trust's NAV return of 117.2% compares with 63.4% for the index, though over five years the gap is narrower at 37.4% against 36.5%.

How the shares have performed

Over one year, the share price total return was 95.7%, ahead of the NAV return as the discount narrowed. Over three years the shares returned 121.4% and over five years 37.9%, according to the factsheet.

The largest holdings at the end of August were Vertex Pharmaceuticals at 4.6%, C4 Therapeutics at 3.6%, Travere Therapeutics at 3.0%, and Vogenx, Biogen, uniQure, Palvella Therapeutics and Arcutis Biotherapeutics at 2.6% to 2.7% each. The top ten made up 28.7% of investments, showing a relatively broad spread.

Within the portfolio, Vogenx gained after a competitor's successful Phase 3 readout in post-bariatric hypoglycaemia, and Travere rose after solid second-quarter earnings. EyePoint fell after its Phase 3 LUGANO trial in macular degeneration missed its primary endpoint. The factsheet also noted that Cybin completed enrolment of its Phase 3 trial of HLP003 in major depressive disorder, while Tango Therapeutics gave back gains made after June pancreatic cancer data.

Gearing was 8.2% at the end of August, within a board limit of 130% of NAV on gross and commitment leverage measures.

What to watch next

Investors will look for the September factsheet to see whether the trust has regained ground against the index after the Moderna-driven gap in August. Clinical trial readouts across its holdings remain the main source of stock-specific risk and opportunity.

The trust's half-year report, covering the six months to 30 September 2026, is the next major milestone; last year's equivalent report was published on 20 November 2025.

Interest rate expectations will also matter, as earlier-stage biotech companies are often sensitive to funding conditions. Buyback activity, if the discount moves beyond 6%, would be another point to watch.